Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03204812
Title Tremelimumab + Durvalumab Chemotherapy Naive CRPC
Recruitment Completed
Gender male
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

prostate adenocarcinoma

Therapies

Durvalumab + Tremelimumab

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
M D Anderson Cancer Center Houston Texas 77030 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field